BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8869067)

  • 1. Antisense oligonucleotides for central nervous system tumors.
    Hall WA; Flores EP; Low WC
    Neurosurgery; 1996 Feb; 38(2):376-83. PubMed ID: 8869067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ; Kant JA; Luger SM; Hijiya N; Zhang J; Zon G; Gewirtz AM
    Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11823-7. PubMed ID: 1281545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides.
    Citro G; Perrotti D; Cucco C; D'Agnano I; Sacchi A; Zupi G; Calabretta B
    Proc Natl Acad Sci U S A; 1992 Aug; 89(15):7031-5. PubMed ID: 1495997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
    Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
    J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
    Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
    Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense strategies for the treatment of hematological malignancies and solid tumors.
    Kronenwett R; Haas R
    Ann Hematol; 1998; 77(1-2):1-12. PubMed ID: 9760146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic antisense and ribozymes.
    Rossi JJ
    Br Med Bull; 1995 Jan; 51(1):217-25. PubMed ID: 7767645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense molecules for targeted cancer therapy.
    Wacheck V; Zangemeister-Wittke U
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense therapeutics and the treatment of CNS disease.
    Jaeger LB; Banks WA
    Front Biosci; 2004 May; 9():1720-7. PubMed ID: 14977581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic and therapeutic significance of MYB expression in human melanoma.
    Hijiya N; Zhang J; Ratajczak MZ; Kant JA; DeRiel K; Herlyn M; Zon G; Gewirtz AM
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4499-503. PubMed ID: 8183937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense approaches to cancer gene therapy.
    Mercola D; Cohen JS
    Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense strategy in hematological malignancies.
    Warzocha K
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.
    Calabretta B; Sims RB; Valtieri M; Caracciolo D; Szczylik C; Venturelli D; Ratajczak M; Beran M; Gewirtz AM
    Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2351-5. PubMed ID: 2006173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic applications of antisense oligonucleotides in asthma and allergy.
    Isidoro-García M; Dávila I
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):171-5. PubMed ID: 19075979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of proliferation by c-myb antisense RNA and oligodeoxynucleotides in transformed neuroectodermal cell lines.
    Raschellà G; Negroni A; Skorski T; Pucci S; Nieborowska-Skorska M; Romeo A; Calabretta B
    Cancer Res; 1992 Aug; 52(15):4221-6. PubMed ID: 1638535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential use of radiolabeled antisense oligonucleotides in oncology.
    Gauchez AS; Du Moulinet D'Hardemare A; Lunardi J; Vuillez JP; Fagret D
    Anticancer Res; 1999; 19(6B):4989-97. PubMed ID: 10697501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.